Ask AI
HER2 Targeted ADCs Clinical Data

CME

Evaluating Clinical Data With HER2-Targeted ADCs in Genitourinary, Gastrointestinal, and Gynecologic Malignancies

Physicians: Maximum of 0.25 AMA PRA Category 1 Credit

Released: August 29, 2025

Expiration: February 28, 2026

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

Based on the phase II DESTINY-PanTumor02 trial and subsequent tumor-agnostic FDA approval of trastuzumab deruxtecan (T-DXd) for patients with unresectable or metastatic HER2-positive disease, which of the following patients would be eligible for treatment?

2.

In the phase II DESTINY-PanTumor02 trial of T-DXd in patients with advanced HER2-positive solid tumors, which of the following efficacy results were reported for T-DXd in the patient population with gynecologic (GYN) cancer?